Abstract
PURPOSE: Obstructive sleep apnea (OSA), a common cause of excessive sleepiness, is associated with impaired mood and other negative outcomes. Nasal continuous positive airway pressure (nCPAP), a standard treatment for OSA, effectively improves airway patency, functional status, and excessive sleepiness. However, some patients experience residual excessive sleepiness even with regular nCPAP use. The novel wake-promoting agent modafinil is indicated for excessive sleepiness associated with narcolepsy, shift work sleep disorder, and residual excessive sleepiness in OSA as an adjunct to nCPAP. We report two double-blind studies of adjunct modafinil for residual excessive sleepiness in OSA patients using nCPAP.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
